Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17149686 | 1.00 | MEN1 (0.51) | MEN1KMT2ARCE1CYP1A2CYP2C19 | |
| SCHEMBL24019697 | 0.84 | HRH4 (0.52) | MEN1KMT2ARCE1HTTALDH1A1 | |
| SCHEMBL25853661 | 0.78 | HRH4 (0.47) | MEN1KMT2ACYP1A2CYP2C19HTT | |
| SCHEMBL13301509 | 0.74 | KMT2A (0.54) | MEN1KMT2ARCE1ALDH1A1LMNA | |
| SCHEMBL21207724 | 0.74 | HRH4 (0.48) | MEN1KMT2ACYP2C19CYP2D6HTT | |
| SCHEMBL6883379 | 0.74 | MEN1 (0.64) | MEN1KMT2ARCE1ALDH1A1LMNA | |
| SCHEMBL19476075 | 0.74 | MEN1 (0.64) | MEN1KMT2ARCE1ALDH1A1LMNA | |
| SCHEMBL17149629 | 0.74 | MEN1 (0.64) | MEN1KMT2ARCE1ALDH1A1LMNA | |
| SCHEMBL17149912 | 0.72 | MEN1 (0.52) | MEN1KMT2ARCE1HTTALDH1A1 | |
| SCHEMBL13597940 | 0.72 | KMT2A (0.61) | MEN1KMT2AHTTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2019-03-21 | — | — | US | disclosed |
| US-10167257-B2 | Indole derivatives for use in medicine | IOMET PHARMA LTD. (GB) | 2019-01-01 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD. (GB) | 2017-04-20 | — | — | US | disclosed |
| WO-2015150097-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IOMET PHARMA LTD (GB) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858319-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | MEN1 3590/4885KMT2A 1638/4885RCE1 1934/4885 |
| US-10167257-B2 | Indole derivatives for use in medicine | IDO1, IDO2, TDO2 | MEN1 3708/4885KMT2A 1690/4885RCE1 1947/4885 |
| US-20170107178-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | MEN1 3708/4885KMT2A 1690/4885RCE1 1947/4885 |
| US-20190084933-A1 | INDOLE DERIVATIVES FOR USE IN MEDICINE | IDO1, IDO2, TDO2 | MEN1 3774/4885KMT2A 1615/4885RCE1 1942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.